PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
NCT ID: NCT07146815
Last Updated: 2025-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
157 participants
INTERVENTIONAL
2022-11-29
2025-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
NCT07027332
Molecular Basis of PCOS in Oocytes and Surrounding Cells
NCT04493788
Post-Prandial Liver Glucose Metabolism in PCOS
NCT03041129
Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
NCT05843955
REFUEL PCOS Study 1
NCT05973175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCOS group
Screening of women with PCOS
FibroScan
Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
MRI PDFF
Performance of an MRI-PDFF to determine amount of liver steatosis.
Control group
Screening of women without PCOS
FibroScan
Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
MRI PDFF
Performance of an MRI-PDFF to determine amount of liver steatosis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FibroScan
Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
MRI PDFF
Performance of an MRI-PDFF to determine amount of liver steatosis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The diagnosis of PCOS based on expert opinion (i.e. according to Rotterdam criteria)
* Able to understand patients information concerning this study
* Able to give written informed consent
Exclusion Criteria
* Exclusion of other causes of liver disease
* Secondary causes of liver steatosis
* Other causes of endocrinological disease
* Diseases that might mimic PCOS
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ziekenhuis Oost-Limburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Z-2022027
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.